|
Press Release |
21 September 2010 |
LiDCO Group Plc
("LiDCO" or the "Company")
Study finds LiDCO's monitor helps reduce mortality in shock patients
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that a study from the University of Iowa has shown that using LiDCO's hemodynamic monitoring technology significantly reduces the mortality rate in patients treated for shock. The results of the study were published in the Journal of Critical Care1.
This study compared the clinical outcomes of 237 shock patients treated following either no hemodynamic monitoring, invasive monitoring (pulmonary artery or central venous catheter) or with LiDCO's minimally invasive LiDCOplus Monitor. Use of the different technologies resulted in significant changes in both the fluid and drugs used to restore the patients' blood pressure and cardiac output. Treatment of patients using LiDCO's monitor significantly reduced the observed mortality rate to 13% against 32% and 20% in the invasively monitored and 37% in the unmonitored patient groups.
In the paper, The University of Iowa investigators concluded: "The results of our study extend the findings of Pearse et al2 who reported that supportive care guided by lithium dilution and arterial waveform [LiDCOplus Monitor] assessments of cardiac output was associated with reduction of perioperative morbidity as compared with conventional assessment."
Dr Terry O'Brien, CEO LiDCO commented: "Fluid and drug management guided by LiDCO's monitoring technology has been shown to reduce complications in high risk surgery, increase the numbers of organs for transplantation and now lower death rates in shock patients. We are seeing increasing documentation of widespread utility in acute care patients with clear positive effects on patient outcome. Further larger multi-center outcome trials are in now in progress in both the UK and the USA with LiDCO chosen as the sole hemodynamic monitor."
References
1. Hata S, Stotts C, Shelksy C et al. Reduced mortality with noninvasive hemodynamic monitoring of shock. Crit Care 2010; doi:10.1016/j.jcrc.2010.07.001
2. Pearse R, Dawson D, Fawcett J, et al. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. Critical Care 2005; 9:R687-93.
- ENDS -
For more information please contact:
|
LiDCO Group Plc |
|
|
Terry O'Brien - Chief Executive John Rowland - Company Secretary |
Tel: +44 (0)20 7749 1500 |
|
FinnCap |
|
|
Geoff Nash / Stephen Norcross / Henrik Persson |
+44 (0)20 7600 1658 |
Media enquiries
|
Abchurch Communications |
|
|
Heather Salmond / Joanne Shears / Simone Elviss / Claire Dickinson |
+44 (0)20 7398 7728 |
|
|
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the measurement, analysis, audit, training and sharing of real-time and historic hemodynamic data, in both critical care units and the operating theatre.
Scientific evidence is increasingly linking the optimisation of patients' hemodynamic status with better outcomes and reduced hospital stays and LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay & overall costs associated with major surgery.
Key Products:
|
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) |
|
|
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: |
|
|
· |
early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
|
· |
quantification of hemodynamic response, |
|
· |
guidance on effective delivery of fluids to ensure the right amount at the right time |
|
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. |
|
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. LiDCO, in collaboration with Covidien (Nasdaq: IDYN), is currently developing a simultaneous brain and hemodynamic monitoring platform to provide clinicians with the market's most evolved fluid and hemodynamic monitoring product for high-risk surgery patients.
Clinical Validation & Education
LiDCO has been selected as the sole technology for two ongoing multi-centre government-funded studies in the UK and US. OPTIMISE is sponsored by the UK Government for optimising cardiovascular management in high-risk abdominal surgery patients and in the US, MOnIToR is a US Government sponsored transplantation donor organ optimisation study. The Company has also developed a hemodynamic workshop at St George's Hospital, London.
LiDCO Distribution Network:
LiDCO products are sold through Covidien's sales force in the US. LiDCO's sells directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.